Project description
Gene therapy for adenosine deaminase deficiency
Deficiency of adenosine deaminase type 2 (DADA2) is a rare, inherited disorder characterised by abnormal inflammation of various tissues and immunodeficiency. It is caused by mutations in the ADA2 gene, rendering it an ideal candidate for gene therapy. The EU-funded DADA2GT project is exploring a gene therapy strategy for correcting ADA2 mutations in homologous haematopoietic stem cells using gene-editing technologies or gene addition by lentiviral vectors. In a clinical setting, these gene-corrected cells will be infused back to the patient. DADA2GT is a proof-of-concept study with a key goal to evaluate the efficacy of gene correction at the preclinical level using patient-derived cells.
Objective
Deficiency of adenosine deaminase type 2 (DADA2) caused by loss-of-function mutations in the ADDeficiency of adenosine deaminase type 2 (DADA2) caused by loss-of-function mutations in the ADA2 gene is a Primary immunodeficiency (PID) diseases characterized by vasculopathy, stroke, intracranial haemorrhages, systemic inflammation, immunodeficiency, and cytopenia. Without proper treatment, DADA2 patients are at high risk of severe disability or death. Targeted pharmacological therapies are not available, and generic immunosuppressive drugs are commonly used with unsatisfactory effectiveness. Haematopoietic stem cell transplantation (HSCT) has proven effective in patients with severe manifestations, but morbidity and mortality are high and hardly acceptable in less severe cases. Thus, safer and targeted therapeutic options for these patients need to be rapidly developed. Based on the observation that HSCT can be successful, it is reasonable to presume that strategies based on ADA2 correction in autologous haematopoietic stem/progenitor cells (HSPCs) may provide new targeted therapeutic approaches for DADA2. The main goal of this project is to establish gene therapy as a new therapeutic option for DADA2. We propose: i) to develop a pre-clinical approach of gene addition mediated by lentiviral vectors targeting ADA2 expression in patient HSPCs; ii) to exploit gene-editing technologies to prove their efficiency for correction of ADA2 mutations. Gene correction efficacy will be assessed as ADA2 expression and activity in vitro in HSPCs and iPSCs isolated from patients, and in mice humanized with patients’ HSPCs. Collectively, this proof-of-concept study will provide new and robust pre-clinical data for the application of lentiviral-mediated HSPC gene therapy in DADA2. This innovative research project is built upon the world-class research expertise developed by the researcher and the host institution in the areas of PIDs, autoinflammatory disorders, and genome engineering.
Fields of science
- medical and health sciencesmedical biotechnologygenetic engineeringgene therapy
- medical and health sciencesmedical biotechnologycells technologiesstem cells
- natural sciencesbiological sciencesgeneticsmutation
- medical and health sciencesbasic medicineneurologystroke
- natural sciencesbiological sciencesgeneticsgenomes
Programme(s)
Funding Scheme
MSCA-IF-EF-SE - Society and Enterprise panelCoordinator
20132 Milano
Italy